Spots Global Cancer Trial Database for Bevacizumab in Treating Patients With Angiosarcoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Bevacizumab in Treating Patients With Angiosarcoma

Official Title: An Open Label Multicenter Phase II Study of Bevacizumab for the Treatment of Angiosarcoma

Study ID: NCT00288015

Conditions

Sarcoma

Interventions

Bevacizumab

Study Description

Brief Summary: RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well bevacizumab works in treating patients with angiosarcoma.

Detailed Description: OBJECTIVES: Primary * Determine the median progression-free survival, in terms of stable disease, of patients with newly diagnosed or recurrent/refractory angiosarcoma treated with bevacizumab. Secondary * Evaluate the treatment effect of bevacizumab on the objective response rate as assessed by modified RECIST criteria in patients with angiosarcoma. * Evaluate the duration of response. * Assess the treatment effect of bevacizumab on duration of overall survival. * Explore the objective response by target tumor density changes on CT scan. * Evaluate the safety and tolerability of bevacizumab in patients with angiosarcoma. OUTLINE: This is an open-label, multicenter study. Patients receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed every 3 to 4 months for 2 years. PROJECTED ACCRUAL: A total of 31 patients will be accrued for this study.